Osteoporosis prevention, detection, and treatment: A mandate for primary care physicians

Postgraduate Medicine

Volumn 107, Issue 7, 2000, Pages 37-56

  Lambing, Cheryl L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN DERIVATIVE; CALCIUM; ESTROGEN; GLUCOCORTICOID; RALOXIFENE; THYROID HORMONE; VITAMIN D;

ARTICLE; BONE ATROPHY; BONE DEVELOPMENT; CALCIUM BALANCE; DENSITOMETRY; DRUG INDUCED DISEASE; ENDOCRINE DISEASE; EXERCISE; FALLING; FRACTURE; HIGH RISK PATIENT; HORMONE SUBSTITUTION; LIFESTYLE; LIVER DISEASE; MULTIPLE MYELOMA; OSTEOPOROSIS; RISK FACTOR; TREATMENT PLANNING;

EID: 0033918359     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2000.06.1124     Document Type: Article

References (40)

1. National Osteopotosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 1998
2. Saadi H, Litaker D, Mills W, et al. Practice variation in the diagnosis and treatment of osteoporosis: a case for more effective physician education in primary care. J Womens Health Gend Based Med 1999;8(6):767-71
3. Cummings SR. Prevention of hip fractures in older women: a population-based perspective. Osteoporos Int 1998;8(Suppl 1):S8-12
4. Donangelo CM. Calcium and osteoporosis. Arch Latinoam Nutr 1997; 47(2Suppl 1):13-6
5. National Osteoporosis Foundation. Boning up on osteoporosis. Washington, DC: National Osteoporosis Foundation, 1998
6. European Foundation for Osteoporosis and the National Osteoporosis Foundation. Consensus development statement: who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 1997;7:1-6
7. McClung MR, McClung BL. Osteoporosis. In: Rakel RE, ed. Conn's current therapy. Philadelphia: Saunders, 1997:581-7
8. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39(11): 1791-801
9. McEvoy G, ed. AHFS drug information. Bethesda, Md; American Society of Health-System Pharmacists, 1999
10. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;33(5)9:292-9
11. Reid D, Cohen S, Pack S, et al. Risedronate is an effective and well-toterated therapy in both the treatment and prevention of corticosteroid-induced osteoporosis. (Abstr) J Bone Miner Res 1998;23(5):W464
12. Healey JH, Paget SA, Williams-Russo P, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996;58(2):73-80
13. Reid IR. Osteoporosis - emerging consensus. Aust N Z J Med 1997;27(6): 643-7
14. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993; 341(8839):72-5
15. Harvey MR, Davidson S, Pearce P. The evaluation of screening for osteoporosis and case-finding in primary care. (Abstr) J Bone Miner Res Mtg 1999;14(Suppl 1): T193
16. Grisso JA, Kelsey JL, O'Brien LA, et al. Risk factors for hip fracture in men. Am J Epidemiol 1997;145(9):786-93
17. Cornuz J, Feskanich D, Willett WC, et al. Smoking, smoking cessation, and risk of hip fracture in women. Am J Med 1999; 106(3):311-4
18. Klein RF. Alcohol-induced bone disease: impact of ethanol on osteoblast proliferation. Alcohol Clin Exp Res 1997;21(3): 392-9
19. Grainge MJ, Coupland CA, Cliffe SJ, et al. Cigarette smoking, alcohol and caffeine consumption, and bone mineral density in postmenopausal women. Osreoporos Int 1998;8(4):355-63
20. Burger H, de Laet CE, van Daele PL, et al. Risk factors for increased bone loss in an elderly population: the Rotterdam Study. Am J Epidemiol 1998;147(9):871-9
21. Madsen KL, Adams WC, Van Loan MD. Effects of physical activity, body weight and composition, and muscular strength on bone density in young women. Med Sci Sports Exerc 1998;30(1):114-20
22. Wolff I, van Croonenborg JJ, Kemper HC, et al. The effect of exercise training on bone mass: a meta-analysis of published control trials in pre- and postmenopausal women. Osteoporos Int 1999;9(1):1-12
23. Cumming RG, Cummings SR, Nevitt MC, et al. Calcium intake and fracture risk: results from the study of osreoporotic fractures. Am J Epidemiol 1997;145(10): 926-34
24. Scott JC. Epidemiology of osteoporosis. Rev Rhum Engl Ed 1997;64(6 Suppl): 10-14S
25. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337(10):670-6
26. LeBoff MS, Kohlmeier L, Hurwitz S, et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999;281 (16):1505-11
27. Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3-year follow-up. J Rheumatol 1996;23(6):995-1000
28. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Calcium. In: Dietary reference intakes for calcium, phosphorous, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press, 1997:71-145
29. Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet 1993;341(8836):11-3
30. Harris ST, Bone HG, Ascott-Evans BH, et al. Alendronate use in postmenopausal women with low bone mass: combination with, comparison to, and use after discontinuation of hormone replacement therapy (HRT). (Abstr) J Bone Miner Res 1999;14(Suppl 1):SU380
31. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996: 348(9041):1535-41
32. Weber TH, Frezner MK. Alendronate increases bone density in male idiopathic osteoporosis, (Abstr) J Bone Miner Res 1999;14(Suppl 1):F345
33. Orwoll E, Ettinger M, Weiss S, et al. Alendronate treatment of osteoporosis in men. (Abstr) J Bone Miner Res 1999; 14(Suppl 1):1205
34. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282(14):1344-52
35. Reid IR. Glucocorticoid osteoporosis - mechanisms and management. Eur J Endocrinol 1997;137(3):209-17
36. Fosamax manufacturer's package insert information. In: Physicians' desk reference. 51st ed. Montvale, NJ: Medical Economics, 1997
37. Fogelman I, Ribot C, Smith R, et al. Risedronate produces dose-dependent increases in bone mineral density in postmenopausal women with low bone mass. (Abstr) Calcif Tissue Int 1999;64(Suppl 1): P79
38. Chestnut C, Baylink DJ, Doyle D, et al. Salmon-calcitonin nasal spray prevents vertebral fractures in established osteoporosis: further interim results of the "PROOF" study. (Abstr) Osteoporos Int 1998;8(Suppl 3):13
39. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women, N Engl J Med 1997; 337(23):1641-7
40. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with taloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282(7):637-45